loading page

Anaphylaxis to drugs: overcoming mast cell unresponsiveness by fake antigens
  • Werner Pichler
Werner Pichler

Corresponding Author:[email protected]

Author Profile


Our understanding of IgE-mediated drug allergy relies on the hapten concept, which is well established in inducing reactions of the immune system to small molecules like drugs. The role of hapten-carrier adducts in re-challenge reactions leading to mast cell degranulation and anaphylaxis is unclear. Based on clinical observations, the speed of adduct formation, skin and in-vitro tests to inert drug molecules, a different explanation of IgE-mediated reactions to drugs is proposed: These are a) A natural role of reduced mast cell (MC) reactivity in developing IgE-mediated reactions to drugs. This MC-unresponsiveness is antigen-specific and covers the serum drug concentrations, but allows reactivity to locally higher concentrations. b) Some non-covalent drug-protein complexes rely on rather affine bindings and have a similar appearance as covalent hapten-carrier adducts. Such drug-protein complexes represent so-called “fake antigens”, as they are unable to induce immunity, but may react with and crosslink preformed drug-specific IgE. As they are formed very rapidly and in high concentrations, they may cause fulminant MC degranulation and anaphylaxis. c) The generation of covalent hapten-protein adducts requires hours, either because the formation of covalent bonds requires time or because first a metabolic step for forming a reactive metabolite is required. This slow process of stable adduct formation has the advantage that it may give time to desensitize mast cells, even in already sensitized individuals. The consequences of this new interpretation of IgE mediated reactions to drugs are potentially wide-reaching for IgE-mediated drug allergy but also allergy in general.
12 May 2020Submitted to Allergy
13 May 2020Submission Checks Completed
13 May 2020Assigned to Editor
14 May 2020Reviewer(s) Assigned
27 May 2020Review(s) Completed, Editorial Evaluation Pending
28 May 2020Editorial Decision: Revise Minor
15 Jun 20201st Revision Received
15 Jun 2020Submission Checks Completed
15 Jun 2020Assigned to Editor
16 Jun 2020Reviewer(s) Assigned
25 Jun 2020Review(s) Completed, Editorial Evaluation Pending
27 Jun 2020Editorial Decision: Revise Minor
08 Jul 20202nd Revision Received
10 Jul 2020Submission Checks Completed
10 Jul 2020Assigned to Editor
11 Jul 2020Reviewer(s) Assigned
13 Jul 2020Review(s) Completed, Editorial Evaluation Pending
14 Jul 2020Editorial Decision: Revise Minor
16 Jul 20203rd Revision Received
17 Jul 2020Submission Checks Completed
17 Jul 2020Assigned to Editor
20 Jul 2020Reviewer(s) Assigned
20 Jul 2020Review(s) Completed, Editorial Evaluation Pending
20 Jul 2020Editorial Decision: Accept
May 2021Published in Allergy volume 76 issue 5 on pages 1340-1349. 10.1111/all.14554